EU Trade Group Backs FDA's $300M Generics Fees Plan

Law360, New York (September 9, 2011, 6:03 PM EDT) -- A European chemical trade group on Friday became the last of three major industry groups to ratify a proposal that calls for generic-drug makers to pay $299 million in annual fees to the U.S. Food and Drug Administration.

European Fine Chemicals Group ratified the proposal for a new program will help ease a crippling backlog in FDA approval for generic medicines by enabling the agency to hire more staff, beef up plant inspections and tackle a backlog of thousands of drug applications, the agency said.

The proposal cleared two American trade organizations,...
To view the full article, register now.